Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Thouvenin J, et al. Among authors: gil t. Oncologist. 2022 Dec 9;27(12):1041-1047. doi: 10.1093/oncolo/oyac158. Oncologist. 2022. PMID: 35979929 Free PMC article.
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Donskov F, et al. Among authors: gil t. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27. Eur J Cancer. 2020. PMID: 31887537 Free PMC article. Clinical Trial.
Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ. Martinez Chanza N, et al. Among authors: gil t, t kint de roodenbeke d. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):199-207. doi: 10.1038/s41391-021-00397-2. Epub 2021 Jun 9. Prostate Cancer Prostatic Dis. 2022. PMID: 34108647
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A. Martinez Chanza N, et al. Among authors: gil t. BMC Cancer. 2021 Dec 2;21(1):1292. doi: 10.1186/s12885-021-08990-3. BMC Cancer. 2021. PMID: 34856936 Free PMC article. Clinical Trial.
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators. de Wit R, et al. N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566937 Clinical Trial.
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.
Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, Lebrun F, Gomez Galdon M, Gil T, Willard-Gallo K, Langouo Fontsa M. Gourari K, et al. Among authors: gil t. Diagnostics (Basel). 2022 Feb 19;12(2):539. doi: 10.3390/diagnostics12020539. Diagnostics (Basel). 2022. PMID: 35204627 Free PMC article.
186 results